SI1315731T1 - 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1h)one derivatives - Google Patents
2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1h)one derivativesInfo
- Publication number
- SI1315731T1 SI1315731T1 SI200130158T SI200130158T SI1315731T1 SI 1315731 T1 SI1315731 T1 SI 1315731T1 SI 200130158 T SI200130158 T SI 200130158T SI 200130158 T SI200130158 T SI 200130158T SI 1315731 T1 SI1315731 T1 SI 1315731T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pyrimidin
- pyridinyl
- tetrahydropyrimido
- dihydroimidazo
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00402410A EP1184383A1 (en) | 2000-09-01 | 2000-09-01 | 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives |
EP00402412A EP1184385A1 (en) | 2000-09-01 | 2000-09-01 | 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
EP01980397A EP1315731B1 (en) | 2000-09-01 | 2001-08-31 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
PCT/EP2001/010726 WO2002018386A1 (en) | 2000-09-01 | 2001-08-31 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1315731T1 true SI1315731T1 (en) | 2005-02-28 |
Family
ID=26073571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200130158T SI1315731T1 (en) | 2000-09-01 | 2001-08-31 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1h)one derivatives |
Country Status (16)
Country | Link |
---|---|
US (3) | US6974819B2 (es) |
EP (1) | EP1315731B1 (es) |
JP (1) | JP2004507546A (es) |
KR (1) | KR100800250B1 (es) |
CN (2) | CN1267432C (es) |
AR (1) | AR030587A1 (es) |
AT (1) | ATE269333T1 (es) |
AU (2) | AU1224902A (es) |
CA (1) | CA2419880C (es) |
DE (1) | DE60103909T2 (es) |
DK (1) | DK1315731T3 (es) |
EA (1) | EA005297B1 (es) |
ES (1) | ES2222396T3 (es) |
SI (1) | SI1315731T1 (es) |
TR (1) | TR200402342T4 (es) |
WO (1) | WO2002018386A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04002629A (es) * | 2001-09-21 | 2005-02-17 | Sanofi Aventis | Derivados de 2-piridinil-6, 7, 8, 9-tetrahidropirimido [1, 2-a] pirimidin-4-ona y 7-piridinil-2, 3-dihidroimidazo [1, 2-a] pirimidin-5(1h) -ona. |
BR0308109A (pt) | 2002-02-28 | 2005-01-04 | Sanofi Aventis | Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila |
EP1454909B1 (en) * | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
EP1460075A1 (en) | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives |
EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
EP1557417B1 (en) * | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
AU2010267814B2 (en) | 2009-07-02 | 2015-07-16 | Sanofi | Novel 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof |
FR2947551B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
JP5655070B2 (ja) * | 2009-07-02 | 2015-01-14 | サノフイ | 新規6,7,8,9−テトラヒドロピリミド{1,2−a}ピリミジン−4−オン誘導体、これらの調製およびこれらの医薬的使用 |
FR2947550B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
CN104906103B (zh) | 2010-12-14 | 2018-05-18 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
CA2945263A1 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
US6004814A (en) | 1998-09-25 | 1999-12-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD71 expression |
-
2001
- 2001-08-31 WO PCT/EP2001/010726 patent/WO2002018386A1/en active IP Right Grant
- 2001-08-31 AU AU1224902A patent/AU1224902A/xx active Pending
- 2001-08-31 ES ES01980397T patent/ES2222396T3/es not_active Expired - Lifetime
- 2001-08-31 TR TR2004/02342T patent/TR200402342T4/xx unknown
- 2001-08-31 AT AT01980397T patent/ATE269333T1/de active
- 2001-08-31 AU AU2002212249A patent/AU2002212249B9/en not_active Ceased
- 2001-08-31 CN CNB018149006A patent/CN1267432C/zh not_active Expired - Fee Related
- 2001-08-31 CN CNB2005100672599A patent/CN100339379C/zh not_active Expired - Fee Related
- 2001-08-31 DK DK01980397T patent/DK1315731T3/da active
- 2001-08-31 JP JP2002523901A patent/JP2004507546A/ja not_active Ceased
- 2001-08-31 EA EA200300151A patent/EA005297B1/ru not_active IP Right Cessation
- 2001-08-31 CA CA2419880A patent/CA2419880C/en not_active Expired - Fee Related
- 2001-08-31 SI SI200130158T patent/SI1315731T1/xx unknown
- 2001-08-31 US US10/362,850 patent/US6974819B2/en not_active Expired - Fee Related
- 2001-08-31 EP EP01980397A patent/EP1315731B1/en not_active Expired - Lifetime
- 2001-08-31 KR KR1020037003062A patent/KR100800250B1/ko not_active IP Right Cessation
- 2001-08-31 AR ARP010104158A patent/AR030587A1/es active IP Right Grant
- 2001-08-31 DE DE60103909T patent/DE60103909T2/de not_active Expired - Lifetime
-
2005
- 2005-09-15 US US11/227,007 patent/US20060014762A1/en not_active Abandoned
-
2007
- 2007-08-20 US US11/841,285 patent/US7566720B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK1315731T3 (da) | 2004-10-11 |
AU2002212249B9 (en) | 2007-01-18 |
CN1449398A (zh) | 2003-10-15 |
CA2419880C (en) | 2010-04-20 |
TR200402342T4 (tr) | 2004-11-22 |
CA2419880A1 (en) | 2002-03-07 |
EA200300151A1 (ru) | 2003-08-28 |
CN1680379A (zh) | 2005-10-12 |
US20040087598A1 (en) | 2004-05-06 |
AR030587A1 (es) | 2003-08-27 |
US6974819B2 (en) | 2005-12-13 |
EP1315731B1 (en) | 2004-06-16 |
AU1224902A (en) | 2002-03-13 |
DE60103909D1 (de) | 2004-07-22 |
CN100339379C (zh) | 2007-09-26 |
EA005297B1 (ru) | 2004-12-30 |
KR20030027103A (ko) | 2003-04-03 |
DE60103909T2 (de) | 2005-09-22 |
EP1315731A1 (en) | 2003-06-04 |
US7566720B2 (en) | 2009-07-28 |
ES2222396T3 (es) | 2005-02-01 |
KR100800250B1 (ko) | 2008-02-01 |
US20080027078A1 (en) | 2008-01-31 |
JP2004507546A (ja) | 2004-03-11 |
CN1267432C (zh) | 2006-08-02 |
ATE269333T1 (de) | 2004-07-15 |
US20060014762A1 (en) | 2006-01-19 |
AU2002212249B2 (en) | 2006-11-30 |
WO2002018386A1 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1430057T1 (sl) | Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati | |
IL151849A0 (en) | Pyrido [2,3-d] pyrimidine and pyrimido [4,5-d] pyrimidine nucleosides | |
AU1224902A (en) | 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives | |
PL370535A1 (en) | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders | |
HK1045510A1 (en) | Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives | |
PL357536A1 (en) | Pyrazolo `4,3-d! pyrimidine derivatives | |
MXPA02012204A (es) | Agentes antivirales de imidazopiridina e imidazopirimidina. | |
IL156536A0 (en) | Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same | |
PL363077A1 (en) | Use of pyrazolo[4,3-d]pyrimidines | |
PL361890A1 (en) | Use of pyrazolo[4,3-d]pyrimidines | |
IL155379A0 (en) | SUBSTITUTED 3,4-DIHYDRO-PYRIMIDO[1,2-a] PYRIMIDINES AND 3,4-DIHYDROPYRAZINO [1,2-a] PYRIMIDINES | |
SI1325010T1 (en) | Substituted 3.4-dihydro-pyrimido (1,2-a)pyrimidines and 3.4-dihydropyrazino (1,2-a)pyrimidines |